Clinical trials: Response, Acute Phase
Postmenopausal Osteoporosis
Pravastatin Reduces Acute Phase Response of Zoledronic Acid
Acute phase response (APR) is one of the most common adverse events in osteoporosis with zoledronic acid treatment. It's reported that this reaction is related to the blockade of the mevalonate pathway, leading to isopentenyl…
- Trial name
- NCT04719481
- Testing
- Pravastatin Sodium 80 MG
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Peking University Third Hospital
Sepsis
Role of RNA Metabolism Alterations in Persistent Immune Dysfunction After Sepsis
This study includes adult ICU patients with sepsis (according to SEPSIS 3.0) or critically ill non-septic patients with severe non-infectious conditions at Louis Mourier Hospital.
- Trial name
- SEPSI-splice (NCT07418801)
- Where
- 2 sites in France
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Phase Response
Disorders of the Acute Phase Response Following Trauma and Invasive Surgery
The purpose of the proposed study is to test these hypotheses through the following aims: 1. To determine if early plasmin activation following severe injury correlates with SIRS, TIC and complications throughout convalescence in…
- Trial name
- NCT03741023
- Testing
- Blood draw (venipuncture or fingerstick)
- Where
- United States
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
SARS-CoV Infection, Covid19
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
This is a phase 3, randomized, observer-blinded, placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of SARS-CoV-2 rS with Matrix-M1 adjuvant in adult participants and adolescent participants.
- Trial name
- NCT04611802
- Testing
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)
- Where
- 154 sites in United States, Mexico and 1 more
- Volunteers
- 33,000 people, healthy volunteers welcome
- Sponsor
- Novavax